FDA To Use New Discipline Review Letters In Communicating ANDA Deficiencies To Generic Drugmakers

FDA will be issuing discipline review letters and information request letters to generic drug applicants to communicate shortcomings in ANDAs. Under GDUFA II, the US agency agreed to send out these letters at the mid-point of the review clock.